Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - Priority Announcement - Inflammatory Bowel Disease

University of Alberta

$45,000.00

Use of Metagenomic Analysis to Identify Viral Populations in Inflammatory Bowel Disease

EF 2009-10

Résumé
Candidate viruses have been proposed as potential etiological agents in inflammatory bowel disease (IBD) but none have stood the test of time. It is clear that some viruses have a complex interaction with the inflammatory disease process; viral infection can manifest with the primary presentation of colitis or cause superimposed disease with use of immunosuppressive therapy. Many viruses, including herpesviridae, rubella and measles virus have been studied both serologically and in tissues, without any clear evidence of candidate virus involvement in IBD. One of the major issues with viral pathogenesis has been distinguishing passenger viruses activated by inflammation and immunosuppression from potentially causal agents. To compound the issue further, it is likely that any pathogen will only cause disease in the genetically susceptible host. Traditionally, most investigators have used the best guess technique for choosing candidate viral agents relying on clues based on clinical observations. Our specific aim now is to broaden our studies and use a metagenomic approach to define the spectrum of viruses in patients with IBD. Metagenomics is defined as the sequenced based analysis of the collective microbial genomes contained in an uncultured environmental sample. Recently, metagenomics has become the methodology of choice to discover new viral agents in cases where an infectious disease process is suspected. In large genome centers, with the new pyrosequencing technology, costs have fallen to $0.001 per base today. These studies will be conducted in the same spirit as the gut microbiome studies sponsored by NIH and MetaHIT by the European Union, except that we plan to investigate and compare the Virome in patients with IBD and healthy subjects to distinguish viral triggers in IBD that will conduct further clinic research, therapy, vaccine production and individualized health care.
Programme
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
194289
Name
Wang Weiwei
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Use of Metagenomic Analysis to Identify Viral Populations in Inflammatory Bowel Disease
Programtype2
Fellowship Programs
Orgnameinp2
University of Alberta
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Keyworddelim
Bioinformatics; Genomics; Inflammatory Bowel Disease; Luminex Platform; Metagenomics; Second-Generation Sequencer; Virology; Virome
Abstract
Candidate viruses have been proposed as potential etiological agents in inflammatory bowel disease (IBD) but none have stood the test of time. It is clear that some viruses have a complex interaction with the inflammatory disease process; viral infection can manifest with the primary presentation of colitis or cause superimposed disease with use of immunosuppressive therapy. Many viruses, including herpesviridae, rubella and measles virus have been studied both serologically and in tissues, without any clear evidence of candidate virus involvement in IBD. One of the major issues with viral pathogenesis has been distinguishing passenger viruses activated by inflammation and immunosuppression from potentially causal agents. To compound the issue further, it is likely that any pathogen will only cause disease in the genetically susceptible host. Traditionally, most investigators have used the best guess technique for choosing candidate viral agents relying on clues based on clinical observations. Our specific aim now is to broaden our studies and use a metagenomic approach to define the spectrum of viruses in patients with IBD. Metagenomics is defined as the sequenced based analysis of the collective microbial genomes contained in an uncultured environmental sample. Recently, metagenomics has become the methodology of choice to discover new viral agents in cases where an infectious disease process is suspected. In large genome centers, with the new pyrosequencing technology, costs have fallen to $0.001 per base today. These studies will be conducted in the same spirit as the gut microbiome studies sponsored by NIH and MetaHIT by the European Union, except that we plan to investigate and compare the Virome in patients with IBD and healthy subjects to distinguish viral triggers in IBD that will conduct further clinic research, therapy, vaccine production and individualized health care.
Competitiondate
200910
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Wang, Weiwei
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Infection & Immunity~ $22,500~ $0~Inst of Nutr Metabolism &Diab~ $22,500~ $0~